Royalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024. In the quarter to June 2026, revenue grew 16.5%, EPS fell 40.0%, free cash flow grew 31.6% and total debt rose 12.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
Follow RPRX
Royalty Pharma PLC (RPRX) Dividend Safety Score
Royalty Pharma PLC's stockrow Dividend Safety Score is 37 out of 100, based on payout ratios, leverage, dividend streak and earnings stability for fiscal 2025.
Dividend Safety Score, annual
Embed this chart
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|---|---|
| FY2025 | 37 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Payout of earnings | 116.82% | — | Fail | 0 |
| Payout of free cash flow | 36.17% | — | Pass | 25 |
| Net debt / EBITDA | 5.22 | — | Fail | 0 |
| Years without a dividend cut | 5 | — | Pass | 12 |
| Years of falling or negative earnings over the last 6 fiscal years | 3 | — | Fail | 0 |
| Dividend Safety Score | Weakly covered | 37 | ||
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| RPRX Royalty Pharma PLC | 37 |
| ROIV Roivant Sciences Ltd. compare | — |
| ARGX argenex SE compare | — |
| INCY Incyte Corporation compare | — |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | — |
| BNTX BioNTech SE Sponsored ADR compare | — |
| ALNY Alnylam Pharmaceuticals, Inc. compare | — |
| RVMD Revolution Medicines, Inc. compare | — |
| GMAB Genmab A/S Sponsored ADR compare | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings